Publications by authors named "S A Hurvitz"

Claim this Profile
C
Characterization of the Safety Profile of Trastuzumab Deruxtecan by Dose: A Pooled Analysis Across DESTINY Studies.
Yeon Hee Park, Javier Cortes, Shanu Modi, Sara A Hurvitz, Giampaolo Bianchini

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis.
Lakshya Seth, Aditya Bhave, Sai Kollapaneni, Viraj Shah, Tarek Nahle, Sara A Hurvitz

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
C Saura, J Cortés, S Modi, S-B Kim, E Hamilton, S A Hurvitz

Ann Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
S A Hurvitz, S Loi, J O'Shaughnessy, A F C Okines, S M Tolaney

Ann Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
J Crown, D Stroyakovskii, D A Yardley, C-S Huang, P A Fasching, S A Hurvitz

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis